Venture capital funds invest in SeaLife Pharma® and accelerate the development of active ingredients against multi-resistant pathogens
Full steam ahead: the equity investment of tecnet equity NÖ Technologiebeteiligungs-Invest GmbH and PP Capital AG in SeaLife Pharma GmbH will give an immediate boost to the discovery and development of new antibiotic active ingredients based on marine organisms. The goal is to develop more effective methods of fighting multi-resistant pathogens, in order to contain the risk that these pathogens pose to mankind.
In recent years, the innovative strategic approach of eco-targeting has allowed the company to isolate a range of highly active marine substances. They are currently in different phases of development and provide several promising potential leads. Through this joint venture, the company’s synthetic chemistry and medical chemistry divisions in particular will be strengthened and additional test platforms in the field of toxicology and bio-activity screening will be developed.
